# A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)

> **NCT02147938** · — · COMPLETED · sponsor: **Astellas Pharma S.A.S.** · enrollment: 578 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02147938
- **Lead sponsor:** Astellas Pharma S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-17
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-05-15
- **Target enrollment:** 578 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02147938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02147938, "A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02147938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*